RxDoctor Payments Data

Demetrius Cook

Psychiatric/Mental Health · Bartlett, TNNPI 1003482993

Payments from drug & device makers

$2,195in general payments, 2019–2025

Across 88 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$354
  • Otsuka America Pharmaceutical, Inc.$329
  • AbbVie$305
  • Johnson & Johnson$289
  • Vanda Pharmaceuticals Inc.$278
  • Supernus Pharmaceuticals, Inc.$249
  • plus $391 from 7 others

What the payments were for

  • Food & beverage$2,195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,195 in reported general payments places this provider in the 70th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$9,502
Medicare patients
110
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$131,257
Invega SustennaPaliperidone Palmitate44$120,928
AristadaAripiprazole Lauroxil12$35,001
RexultiBrexpiprazole20$29,933
VraylarCariprazine Hcl14$19,664
Lurasidone Hcl24$15,346
Aripiprazole77$6,904
Haloperidol Decanoate110$4,358
Quetiapine Fumarate113$2,231
Ziprasidone Hcl13$2,138
Divalproex Sodium ErDivalproex Sodium38$2,067
Hydroxyzine Hcl53$1,775
Olanzapine51$1,754
Benztropine Mesylate154$1,636
Fluphenazine Decanoate63$1,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$37$131,25716 claims
Johnson & JohnsonInvega Sustenna$289$120,92844 claims
Alkermes, Inc.Aristada$354$35,00112 claims
Otsuka America Pharmaceutical, Inc.Rexulti$329$29,93320 claims
AbbVieVraylar$305$19,66414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Bartlett

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →